

## ALEMBIC LIMITED

Regd.Office: Alembic Road, Vadodara 390 003 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2011

(Rs in Lacs)

							(Rs in Lacs
			Quarter			Nine Months	
		Ended	Ended	Ended	Ended	Ended	Year Ended
	Particulars	on 31st	on 30th	on 31st	on 31st	on 31st	on 31st
		December	September	December	December	December	March
		2011	2011	2010	2011	2010	2011
		(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
1	(a) Net Sales / Income from Operations	,					
	Domestic	2,728	2,739	25,326	9,257	69,692	19,443
	Exports	255	107	12,053	818	32,508	2,248
	Total	2,983	2,846	37,379	10,075	102,200	21,691
	Less : Excise Duty	239	239	861	798	1,510	1,613
	Net Sales / Income from Operations	2,744	2,607	36,518	9,277	100,690	20,078
	(b) Other Operating Income	66	102	109	197	262	115
		Attachment van antack automos vervan					
Tota	al Income	2,810	2,709	36,627	9,474	100,952	20,193
2	Expenditure						
	(a) Decrease/(increase) in stock in trade and work in progress	(77)	(972)	(57)	(2,108)	(2,254)	369
	(b) Consumption of Raw Materials & Packing Materials	1,320	2,142	13,714	6,613	38,074	12,639
	(c) Purchase of traded goods	- 0	-	4,066	<b>.</b>	13,494	70
	(d) Employees' Cost	640	835	4,028	2,007	12,138	2,692
	(e) Research and Development Expense	=	in the second se	1,012	(=)	3,304	184
	(f) Excise Duty	(97)	93	(167)	99	554	(21
	(g) Other Expenditure	1,191	1,117	8,109	3,243	22,476	3,959
-	Total	2,977	3,216	30,705	9,854	87,786	19,892
3	Profit from Operations before Other Income, Interest, Depreciation	(167)	(507)	5,922	(380)	13,166	301
. ,	Exceptional Items						
4	Other Income	103	670	65	845	206	262
5	Profit/(Loss) before Interest, Depreciation, & Exceptional Items	(64)	163	5,987	465	13,372	563
6	Depreciation	256	255	1,139	836	3,397	1,007
7	Interest (Net)	143	108	791	387	1,896	240
8	Profit/(Loss) after Interest but before Exceptional Items	(463)	(200)	4,057	(758)	8,079	(684
9	Exceptional Items - Voluntary Retirement Scheme	=	9	369	248	369	422
10	Net Profit / (Loss) from Ordinary Activities before Tax	(463)	(209)	3,688	(1,006)	7,710	(1,106
11	Tax Expense				10.7	· ·	
	Less: Provision for Wealth Tax	3	7	3	10	10	13
	Less: Provision for Current Tax			779		1,461	S <del></del>
	Less/(Add): Provision for Deferred Tax Liability/(Assets)	(22)	(37)	(178)	(106)	(169)	(105
	Less/(Add): Provision of Income Tax of earlier years written back (Net)	-	-	-	-2	(1)	276
12	Net Profit / (Loss) from Ordinary Activities after Tax	(444)	(179)	3,084	(910)	6,409	(1,290
13	Paid up Equity Share Capital	2,670	2,670	2,670	2,670	2,670	2,670
	( Face value of share Rs 2/- )						
14	Reserves excluding Revaluation Reserve	=	-	-	H	-	6,234
15	Basic & Diluted EPS (Not Annualised)	(0.33)	(0.13)	2.31	(0.68)	4.80	(0.97
16	Public Shareholding				9 15		
	- Number of Shares	48,763,089	48,763,089	48,763,089	48,763,089	48,763,089	48,763,089
	- Percentage of Shareholding	36.52	36.52	36.52	36.52	36.52	36.52
17	Promoters and Promoter Group Shareholding						
	Fully Non - Encumbered	9					
	Number of Shares	84,752,825	84,752,825	84,752,825	84,752,825	84,752,825	84,752,825
	Percentage of Shares (as a % of the total	100	100	100	100	100	100
	shareholding of promoter and promoter group)		d :				
	Percentage of Shares (as a % of the total	63.48	63.48	63.48	63.48	63.48	63.48
	share capital of the Company)						
	general medical conserver in the conservation of COSC (COSC COSC COSC COSC COSC COSC COS						





## Notes:

- 1 The above results have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and approved by the Board of Directors.
- 2 In pursuance of Honourable Gujarat High Court's Order, the Pharmaceutical Undertaking of the Company is demerged and transferred to Alembic Pharmaceuticals Limited w.e.f. appointed date 1st April 2010. Accordingly, above results for current quarter/period do not include results of said pharmaceutical undertaking and hence are not comparable with corresponding figures of previous quarter/period.

Figures for the corresponding nine months period of the previous financial year for the 'Remaining undertaking' are produced below for comparison purpose

		(Rs.in Lacs)				
Particulars	For the Nine Months ended on 31.12.2011	For the Nine Months ended on 31.12.2010				
Sales	10075	16305				
PBT	(1006)	(1653)				
PAT	(910)	(1432)				

The previous year's figures have been re-grouped/re-arranged wherever necessary.

- 3 The Company has started a real estate project for residential use. The project is in initial stage and no revenue/profit is recognised in the current quarter/ nine months period and therefore, the Company has reported only pharmaceutical segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 Details of Investors' Complaints for the quarter ended on 31st Dec, 2011: Unresolved at the beginning of the quarter-NIL Received during the quarter 6, Disposed off during the quarter 6, Unresolved at the end of the quarter NIL.

For Alembic Limited

Chirayu Amin

Chairman

Place : Vadodara

Date: 14th February, 2012

Visit us at www.alembiclimited.com

## K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

# F-7 Laxmi Mills Shakti Mills Lane (Off Dr E Moses Rd) Mahalaxmi Mumbai 400 011 India Tel: 91 22 2493 2502 / 6655 1770 Fax: 91 22 6655 1774 Grams: VERIFY www.KSAiyar.com Mail@KSAiyar.com

To, The Board of Directors; Alembic Limited; Alembic Road, Vadodara.

## RE: LIMITED REVIEW OF THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st December, 2011.

- 1. We have reviewed the accompanying statement of unaudited financial results of Alembic Limited for the quarter ended on 31st December, 2011 attached herewith except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management and have not been audited by us. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to express a conclusion on this interim financial information based on our review. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors.
  - 2. We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
  - 3. Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.
Chartered Accountants
FRN: 100186W

Rajesh S. Joshi

Partnef/ M.No. 38526

Place: Vadodara

Date: 14th February, 2012